Which has stronger valuation and earnings, NAVB or CMRA?

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Navidea Biopharmaceuticals $8.13K 0.00 -$15.18M -$0.21 N/A Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A

Is NAVB or CMRA more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Comera Life Sciences N/A N/A N/A

Which has higher earnings & valuation, CMRA or GNCA?

Comera Life Sciences has higher earnings, but lower revenue than Genocea Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is CMRA or GNCA more profitable?

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Genocea Biosciences N/A -182.88% -62.76%

Is PXMD or CMRA more profitable?

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Comera Life Sciences N/A N/A N/A

Which has preferable valuation and earnings, CMRA or GNCAQ?

Genocea Biosciences has lower revenue, but higher earnings than Comera Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Comera Life Sciences $1.00M 0.00 -$18M -$0.31 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is CMRA or GNCAQ more profitable?

Company Net Margins Return on Equity Return on Assets Comera Life Sciences N/A N/A N/A Genocea Biosciences N/A N/A N/A

Is SYRS or CMRA more profitable?

Comera Life Sciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Syros Pharmaceuticals N/A -3,369.56% -97.04% Comera Life Sciences N/A N/A N/A

Comera Life Sciences (CMRA) Competitors

Compare

CMRA vs. NAVB, GNCA, PXMD, GNCAQ, and SYRS

Should you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Genocea Biosciences (GNCAQ), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Comera Life Sciences	Neutral

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Comera Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Comera Life Sciences	N/A	N/A	N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Comera Life Sciences (NASDAQ:CMRA) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

0.6% of Genocea Biosciences shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Comera Life Sciences has higher earnings, but lower revenue than Genocea Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Genocea Biosciences	Neutral

Comera Life Sciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

Comera Life Sciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market.

Summary

Comera Life Sciences beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Comera Life Sciences	Neutral

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Comera Life Sciences	N/A	N/A	N/A

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does Comera Life Sciences compare to Genocea Biosciences?

Comera Life Sciences (NASDAQ:CMRA) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Genocea Biosciences has lower revenue, but higher earnings than Comera Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Comera Life Sciences	N/A	N/A	N/A
Genocea Biosciences	N/A	N/A	N/A

Comera Life Sciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Comera Life Sciences	Neutral
Genocea Biosciences	Neutral

Summary

Comera Life Sciences beats Genocea Biosciences on 2 of the 3 factors compared between the two stocks.

How does Comera Life Sciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Comera Life Sciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
Comera Life Sciences	N/A	N/A	N/A

Comera Life Sciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.01	-$164.57M	-$3.03	N/A
Comera Life Sciences	$1.00M	0.00	-$18M	-$0.31	N/A

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
Comera Life Sciences	Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Comera Life Sciences beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CMRA vs. The Competition

Export

Metric	Comera Life Sciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	-$18M	-$3.71M	$3.57B	$337.01M

Comera Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMRA Comera Life Sciences	N/A	N/A	N/A	N/A	$3K	$1.00M	N/A	2
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2
GNCAQ Genocea Biosciences	N/A	N/A	N/A	N/A	$5K	N/A	N/A	70	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Comera Life Sciences (CMRA) Competitors

CMRA vs. NAVB, GNCA, PXMD, GNCAQ, and SYRS

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Summary

How does Comera Life Sciences compare to Genocea Biosciences?

Summary

How does Comera Life Sciences compare to PaxMedica?

Summary

How does Comera Life Sciences compare to Genocea Biosciences?

Summary

How does Comera Life Sciences compare to Syros Pharmaceuticals?

Summary

CMRA vs. The Competition

Comera Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Comera Life Sciences (CMRA) Competitors

CMRA vs. NAVB, GNCA, PXMD, GNCAQ, and SYRS

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Does the media favor NAVB or CMRA?

Which has stronger valuation and earnings, NAVB or CMRA?

Do institutionals and insiders have more ownership in NAVB or CMRA?

Is NAVB or CMRA more profitable?

Which has more volatility & risk, NAVB or CMRA?

Summary

How does Comera Life Sciences compare to Genocea Biosciences?

Do institutionals and insiders have more ownership in CMRA or GNCA?

Which has higher earnings & valuation, CMRA or GNCA?

Does the media prefer CMRA or GNCA?

Is CMRA or GNCA more profitable?

Which has more risk and volatility, CMRA or GNCA?

Summary

How does Comera Life Sciences compare to PaxMedica?

Does the media favor PXMD or CMRA?

Do institutionals & insiders hold more shares of PXMD or CMRA?

Which has more volatility and risk, PXMD or CMRA?

Is PXMD or CMRA more profitable?

Which has better valuation and earnings, PXMD or CMRA?

Summary

How does Comera Life Sciences compare to Genocea Biosciences?

Which has preferable valuation and earnings, CMRA or GNCAQ?

Is CMRA or GNCAQ more profitable?

Which has more risk and volatility, CMRA or GNCAQ?

Does the media favor CMRA or GNCAQ?

Summary

How does Comera Life Sciences compare to Syros Pharmaceuticals?

Which has more volatility and risk, SYRS or CMRA?

Is SYRS or CMRA more profitable?

Which has better earnings & valuation, SYRS or CMRA?

Does the media favor SYRS or CMRA?

Do insiders and institutionals believe in SYRS or CMRA?

Summary

CMRA vs. The Competition

Comera Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools